"Inflammation and Procalcitonin Predict Success, or Not, of Lung Cancer Treatment" Antonio Giordano

Updated: Oct 5

Precision medicine often looks for biomarkers to predict the best possible outcomes for different cancer treatments. This new study from researchers working with Antonio Giordano at Sbarro Health Research Organization shows how high levels of inflammation and signs bacterial infection in the bloodstream indicate a poor prognosis for lung cancer treated with immune checkpoint blockade.


The original article is posted by NewsWise and it can be accessed by this link: "Inflammation and Procalcitonin Predict Success, or Not, of Lung Cancer Treatment"


Dr Antonio Giordano, Founder & Director of Sbarro Health Research Organization, based at Temple University, Philadelphia.



Dr Antonio Giordano is a faculty at Temple University, Philadelphia and an italian-american geneticist.
Dr Antonio Giordano, Founder & Director of Sbarro Health Research Organization


About Sbarro Health Research Organization (SHRO): The Sbarro Health Research Organization is a non-profit charity committed to funding excellence in basic genetic research to cure and diagnose cancer, cardiovascular diseases, diabetes and related chronic illnesses and to foster the training of young doctors in a spirit of professionalism and humanism (www.shro.org)


Sbarro Health Research Organization (SHRO) social media channels [Facebook, LinkedIn, Twitter, Instagram]


Connect with Dr Antonio Giordano, Sbarro Health Research Organization


president@shro.org (Facebook, LinkedIn, Twitter, Instagram)

2 views0 comments